Old Articles: <Older 7891-7900 Newer> |
|
The Motley Fool September 20, 2011 Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
The Motley Fool September 17, 2011 Chris Seper |
Pozen's Digital Marketing Plan: A Prescription for the Pharma Industry? The company looks to get in tune with social media. |
The Motley Fool September 16, 2011 Brian Orelli |
A Shrinking Obesity Market VIVUS figures some sales are better than none for its obesity drug Qnexa. |
The Motley Fool September 15, 2011 Brian Orelli |
Stop Worrying About Pfizer's Breakup Sometimes you just have to trust management. |
The Motley Fool September 15, 2011 Frank Vinluan |
GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago. |
Pharmaceutical Executive September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
Pharmaceutical Executive September 1, 2011 |
Pharma and Social Media: Ready to Make Nice? The time is right for industry to overcome its social media phobia once and for all. |
Pharmaceutical Executive September 1, 2011 |
Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders. |
Pharmaceutical Executive September 1, 2011 |
Should the US Gamble with Risk Sharing? Especially when payers come to the table holding the best cards, leaving industry second-guessing its strategy. |
Pharmaceutical Executive September 1, 2011 |
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? |
<Older 7891-7900 Newer> Return to current articles. |